Archieve Issue

Follicular hyperkeratinisation, bacterial colonization, and excessive sebum production are the hallmarks of acne vulgaris, a chronic inflammatory skin condition that frequently results in papules, pustules, and scarring. Anti-acne medications like benzoyl peroxide, retinoids, and antibiotics are frequently administered via traditional topical formulations like creams, gels, and lotions. However, poor skin penetration, instability, and frequent dose requirements restrict their therapeutic efficacy and lower patient compliance. Topical drug delivery methods based on nanoemulsions have shown promise in addressing these issues by improving drug solubility, stability, and bioavailability. Oil, water, and surfactant dispersions that are thermodynamically or kinetically stable and have droplet sizes that are usually between 20 and 200 nm are known as nanoemulsions. Improved drug penetration through the stratum corneum and targeted delivery to pilosebaceous units, the main location of acne pathology, are made possible by their enormous surface area and small droplet size. The formulation design and characterization techniques of nanoemulsion-based acne treatment systems are the main topics of this review. The choice of oils, surfactants, and co-surfactants, optimization of droplet size, zeta potential, viscosity, and stability, and drug loading methods appropriate for hydrophilic and lipophilic drugs are important factors to take into account. Particle size analysis, entrapment efficiency, in vitro drug release, ex vivo skin penetration, and deposition investigations are examples of characterization techniques that are emphasized. Additionally, current developments involving combination treatments and herbal actives are covered. In comparison to traditional formulations, nanoemulsion-based topical systems offer increased penetration, controlled release, less irritation, and better patient adherence, making them a suitable platform for enhancing anti-acne therapy.

Impurity profiling is a critical aspect of pharmaceutical quality control, encompassing the identification, characterization, quantification, and regulation of impurities in both drug substances and drug products. Impurities may originate from synthetic processes, degradation pathways, residual solvents, or interactions with packaging materials, and their presence can significantly impact drug safety, efficacy, and regulatory compliance. A wide range of advanced analytical techniques, including chromatographic methods (HPLC, GC, UPLC), spectroscopic tools (NMR, IR), and mass spectrometric approaches (LC-MS/MS, GC-MS), are employed for impurity profiling. International regulatory frameworks, particularly ICH guidelines Q3A–Q3D and M7, provide clear specifications for impurity limits and control strategies. This report outlines the various sources and classifications of impurities—organic, inorganic, residual solvents, and genotoxic—and emphasizes the role of Quality by Design (QbD), method validation, and risk assessment in establishing robust impurity control.

Mistake proofing solution are design-based techniques used in industry to prevent errors during the production process. error proofing widely known as Poka yoke is proactive quality management strategy focused on preventing human error before they lead to defect. Originating from the Toyota production system the principle has expanded beyond manufacturing into service and administrative domains as organizations pursue higher quality and operational excellence. The research explores how error proofing integrates into enterprise quality management framework, examines systematic methods for implementing error proofing controls and highlights key application areas demonstrating its effectiveness. Its role in modern quality systems including lean and six sigma, suggest Poka yoke is a foundational error preventive mechanism crucial for sustainable quality improvement. Error proofing system is discussing the operational mechanism of the enterprises quality management error proofing system with the analysis of the process of quality management error proofing.

Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuron loss. Levodopa, the primary treatment, is commonly paired with carbidopa to enhance brain bioavailability and minimize peripheral side effects. However, challenges such as motor fluctuations and limited absorption necessitate advanced drug delivery approaches. These include extended-release, gastro-retentive, and transdermal systems, as well as innovative formulations like the Accordion Pill®, DM-1992, and subcutaneous infusions like ND0612. Such strategies aim to provide sustained plasma levels, reduce dosing frequency, and improve patient compliance and therapeutic outcomes. Ongoing research is vital for optimizing delivery and enhancing the quality of life in PD management. Innovative drug delivery systems for levodopa/carbidopa in Parkinson’s disease aim to overcome motor fluctuations and improve patient outcomes. Approaches include 3D-printed scaffolds, inhalable powders, enteral suspensions, segmented tablets, and extended-release formulations, offering controlled and personalized therapy. These strategies enhance bioavailability, stability, and symptom management in advanced PD care. Advanced strategies in Levodopa delivery for Parkinson’s disease include PEGylation, lipid nanoparticle conjugation, and ligand-mediated targeting for enhanced brain penetration. Functionalized nanoparticles improve bioavailability, reduce side effects, and offer controlled release. Clinical trials like ELLDOPA, STRIDE-PD, and CALM-PD guide optimized therapy, shaping future personalized treatment approaches.

Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder characterized by reflux of gastric contents into the esophagus, leading to troublesome symptoms and potential complications. Its pathogenesis involves dysfunction of the anti-reflux barrier, impaired esophageal clearance, and altered mucosal defense mechanisms. Multiple risk factors, including obesity, lifestyle habits, and anatomical abnormalities, contribute to disease progression. Diagnosis is based on clinical evaluation supported by endoscopy and reflux monitoring. Management includes lifestyle modification, pharmacotherapy primarily proton pump inhibitors and advanced endoscopic or surgical interventions. Recent advances emphasize phenotype-based and precision medicine approaches to improve long-term outcomes and patient-centered care.